Role of Plasminogen Activator Inhibitor Type 1 (PAI-1) in PCOS Patients
plasminogen activator inhibitor type 1 PAI-1 Polycystic Ovarian Syndrome PCOS body mass index BMI waist-to-hip ratio fasting glucose insulin levels triglycerides low-density lipoprotein LDL insulin resistance Homeostatic Model Assessment for Insulin Resistance HOMA-IR atherosclerosis cardiovascular diseases menstrual disturbances infertility
Studysummary This study found that women with PCOS had significantly elevated plasma levels of PAI-1, which correlated with insulin resistance and obesity.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on ijrcog.org →